PIKfyve inhibitors restrict replication of multiple human coronaviruses in vitro but not in a murine model of COVID-19
收藏NIAID Data Ecosystem2026-03-14 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP376844
下载链接
链接失效反馈官方服务：
资源简介：
Apilimod is being considered as a COVID-19 therapeutic in a Phase II efficacy trial. However, at the time of writing, there are no published efficacy data in human trials or animal COVID-19 models. While Apilimod and other PIKfyve inhibitors have potent antiviral activity in various cell lines against multiple human coronaviruses, these compounds worsen disease in a COVID-19 murine model when given prophylactically or therapeutically.
创建时间：
2022-12-01
